High seroprevalence of SARS-CoV-2 but low infection fatality ratio eight months after introduction in Nairobi, Kenya.


Journal

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
ISSN: 1878-3511
Titre abrégé: Int J Infect Dis
Pays: Canada
ID NLM: 9610933

Informations de publication

Date de publication:
Nov 2021
Historique:
received: 15 05 2021
revised: 12 08 2021
accepted: 26 08 2021
pubmed: 6 9 2021
medline: 15 12 2021
entrez: 5 9 2021
Statut: ppublish

Résumé

The lower than expected COVID-19 morbidity and mortality in Africa has been attributed to multiple factors, including weak surveillance. This study estimated the burden of SARS-CoV-2 infections eight months into the epidemic in Nairobi, Kenya. A population-based, cross-sectional survey was conducted using multi-stage random sampling to select households within Nairobi in November 2020. Sera from consenting household members were tested for antibodies to SARS-CoV-2. Seroprevalence was estimated after adjusting for population structure and test performance. Infection fatality ratios (IFRs) were calculated by comparing study estimates with reported cases and deaths. Among 1,164 individuals, the adjusted seroprevalence was 34.7% (95% CI 31.8-37.6). Half of the enrolled households had at least one positive participant. Seropositivity increased in more densely populated areas (spearman's r=0.63; p=0.009). Individuals aged 20-59 years had at least two-fold higher seropositivity than those aged 0-9 years. The IFR was 40 per 100,000 infections, with individuals ≥60 years old having higher IFRs. Over one-third of Nairobi residents had been exposed to SARS-CoV-2 by November 2020, indicating extensive transmission. However, the IFR was >10-fold lower than that reported in Europe and the USA, supporting the perceived lower morbidity and mortality in sub-Saharan Africa.

Sections du résumé

BACKGROUND BACKGROUND
The lower than expected COVID-19 morbidity and mortality in Africa has been attributed to multiple factors, including weak surveillance. This study estimated the burden of SARS-CoV-2 infections eight months into the epidemic in Nairobi, Kenya.
METHODS METHODS
A population-based, cross-sectional survey was conducted using multi-stage random sampling to select households within Nairobi in November 2020. Sera from consenting household members were tested for antibodies to SARS-CoV-2. Seroprevalence was estimated after adjusting for population structure and test performance. Infection fatality ratios (IFRs) were calculated by comparing study estimates with reported cases and deaths.
RESULTS RESULTS
Among 1,164 individuals, the adjusted seroprevalence was 34.7% (95% CI 31.8-37.6). Half of the enrolled households had at least one positive participant. Seropositivity increased in more densely populated areas (spearman's r=0.63; p=0.009). Individuals aged 20-59 years had at least two-fold higher seropositivity than those aged 0-9 years. The IFR was 40 per 100,000 infections, with individuals ≥60 years old having higher IFRs.
CONCLUSION CONCLUSIONS
Over one-third of Nairobi residents had been exposed to SARS-CoV-2 by November 2020, indicating extensive transmission. However, the IFR was >10-fold lower than that reported in Europe and the USA, supporting the perceived lower morbidity and mortality in sub-Saharan Africa.

Identifiants

pubmed: 34481966
pii: S1201-9712(21)00696-2
doi: 10.1016/j.ijid.2021.08.062
pmc: PMC8411609
pii:
doi:

Substances chimiques

Antibodies, Viral 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

25-34

Subventions

Organisme : FIC NIH HHS
ID : D43 TW011519
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI151799
Pays : United States
Organisme : CGH CDC HHS
ID : U01 GH002143
Pays : United States

Informations de copyright

Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Auteurs

Isaac Ngere (I)

Washington State University (WSU) Global Health Kenya, Nairobi, Kenya; Paul G. Allen School of Global Health, Washington State University (WSU), Pullman, USA.

Jeanette Dawa (J)

Washington State University (WSU) Global Health Kenya, Nairobi, Kenya; Paul G. Allen School of Global Health, Washington State University (WSU), Pullman, USA.

Elizabeth Hunsperger (E)

Center for Global Health, US Centers for Disease Control and Prevention (CDC)-Kenya, Nairobi, Kenya.

Nancy Otieno (N)

Center for Global Health Research, Kenya Medical Research Institute (KEMRI), Kisumu, Kenya.

Moses Masika (M)

KAVI-Institute for Clinical Research, University of Nairobi, Nairobi, Kenya.

Patrick Amoth (P)

Kenya Ministry of Health, Nairobi, Kenya.

Lyndah Makayotto (L)

Department of Health, Nairobi Metropolitan Services, Nairobi, Kenya.

Carolyne Nasimiyu (C)

Washington State University (WSU) Global Health Kenya, Nairobi, Kenya; Paul G. Allen School of Global Health, Washington State University (WSU), Pullman, USA.

Bronwyn M Gunn (BM)

Paul G. Allen School of Global Health, Washington State University (WSU), Pullman, USA.

Bryan Nyawanda (B)

Center for Global Health Research, Kenya Medical Research Institute (KEMRI), Kisumu, Kenya.

Ouma Oluga (O)

Department of Health, Nairobi Metropolitan Services, Nairobi, Kenya.

Carolyne Ngunu (C)

Department of Health, Nairobi Metropolitan Services, Nairobi, Kenya.

Harriet Mirieri (H)

Washington State University (WSU) Global Health Kenya, Nairobi, Kenya; Paul G. Allen School of Global Health, Washington State University (WSU), Pullman, USA.

John Gachohi (J)

Washington State University (WSU) Global Health Kenya, Nairobi, Kenya; Paul G. Allen School of Global Health, Washington State University (WSU), Pullman, USA; School of Public Health, Jomo Kenyatta University of Agriculture and Technology, Kiambu, Kenya.

Doris Marwanga (D)

Washington State University (WSU) Global Health Kenya, Nairobi, Kenya; Paul G. Allen School of Global Health, Washington State University (WSU), Pullman, USA.

Patrick K Munywoki (PK)

Center for Global Health, US Centers for Disease Control and Prevention (CDC)-Kenya, Nairobi, Kenya.

Dennis Odhiambo (D)

Center for Global Health Research, Kenya Medical Research Institute (KEMRI), Kisumu, Kenya.

Moshe D Alando (MD)

Center for Global Health Research, Kenya Medical Research Institute (KEMRI), Kisumu, Kenya.

Robert F Breiman (RF)

Emory University, Atlanta, USA.

Omu Anzala (O)

KAVI-Institute for Clinical Research, University of Nairobi, Nairobi, Kenya.

M Kariuki Njenga (MK)

Washington State University (WSU) Global Health Kenya, Nairobi, Kenya; Paul G. Allen School of Global Health, Washington State University (WSU), Pullman, USA.

Marc Bulterys (M)

Center for Global Health, US Centers for Disease Control and Prevention (CDC)-Kenya, Nairobi, Kenya.

Amy Herman-Roloff (A)

Center for Global Health, US Centers for Disease Control and Prevention (CDC)-Kenya, Nairobi, Kenya.

Eric Osoro (E)

Washington State University (WSU) Global Health Kenya, Nairobi, Kenya; Paul G. Allen School of Global Health, Washington State University (WSU), Pullman, USA. Electronic address: eric.osoro@wsu.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH